A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.